The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies in the United States

Abstract

Key points Long-acting antiretroviral treatment regimens currently in development will increase choice and may improve clinical outcomes in persons with HIV infection. Creating a discrete choice experiment (DCE) based on hypothetical attributes of products in development requires detailed input from experts and stakeholders, but can provide important data to help guide product development and understand patient preferences. While key informant interviewers with product developers, researchers, and clinicians can provide guidance to inform DCE development, careful pilot testing will be needed to ensure the salience and comprehension of the different attributes and levels identified.